Integrated Care Strategies to Address the Impact of Residual Symptoms on Functional Outcomes in MDD
neuroscienceCME WebcastPremiere Date: Friday, June 16, 2017
This activity offers CE credit for:%>
- Nurse Practitioners (AANP)
- Physician Assistants (AAPA)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Saturday, June 16, 2018
|Roger S. McIntyre, MD, FRCPC (Moderator)
Professor of Psychiatry and Pharmacology
University of Toronto
Brain and Cognition Discovery Foundation (BCDF)
Head, Mood Disorders Psychopharmacology Unit
University Health Network
|Catherine Judd, MS, PA-C, CAQ-Psy, DFAAPA
Clinical Assistant Professor
Department of Physician Assistant Studies
UT Southwestern Medical Center School of Health Professions
Mental Health and Behavioral Medicine
Parkland Health and Hospital System
|Gregory W. Mattingly, MD
Associate Clinical Professor
Washington University School of Medicine
St. Louis, MO
Midwest Research Group
St. Charles, MO
Depression is one of the leading causes of disability worldwide. It affects individuals, families, businesses, and society and is common in patients seeking care in the primary care setting. Approximately 55% of patients will respond to treatment with the initial antidepressant.1 Yet, even in those patients who respond to treatment and achieve remission, residual symptoms can significantly inhibit functionality and increase the risk of relapse and recurrence.2
Despite these challenges, MDD can be effectively managed, particularly when the clinician and patient mutually define what remission means to the patient and work together towards achieving sustained remission.
This CME Outfitters symposium on MDD features expert faculty offering new perspectives on treating this pervasive disorder, highlights residual symptoms as a challenge to clinicians, and ways to engage with patients to optimize management of all symptoms.
1. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D, implications for clinical practice. Am J Psychiatry. 2006;163:28-40.
2. Zajecka JM. Residual symptoms and relapse: mood, cognitive symptoms, and sleep disturbances. J Clin Psychiatry. 2013;74(Suppl 2):9-13.
At the end of this CE activity, participants should be able to:
- Recognize the relationship between residual cognitive symptoms and functional impairment in patients with MDD.
- Assess all of the symptoms of MDD including cognitive and residual symptoms with a validated screening tool at each visit.
- Engage patients in shared decision-making to optimize their treatment options to manage all symptoms of MDD.
Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc. and Lundbeck.
Physician assistants and nurse practitioners managing patients with major depression.
AANP Credit (Nurse Practitioners):
This activity is approved 2.0 contact hour(s) of continuing education (which includes 1.0 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 17052683. This activity was planned in accordance with AANP CE Standards and Policies.
AAPA Credit (Physician Assistants):
This program has been reviewed and is approved for a maximum of 2.0 AAPA Category 1 CME credits by the AAPA Review Panel. Participants should only claim credit commensurate with their participation in the CME activity. This program was planned in accordance with AAPA’s CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs.
Approval is valid for one year from the issue date of 06/16/2017.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. McIntyre reports that he receives research grants from Allergan; AstraZeneca; Janssen Pharmaceuticals Inc.; Lundbeck; Otsuka; Pfizer Inc.; Purdue Pharma; and Shire.
He serves on the advisory board for AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb Company; Forest Laboratories, Inc.; Janssen Pharmaceuticals, Inc.; Johnson & Johnson; Lundbeck; Mitsubishi Tanabe Pharma Corporation; Moksha8 Pharmaceuticals Inc.; Otsuka; Pfizer Inc.; Purdue Pharma; Shire; Sunovion Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Limited.
He receives speaker's fees from AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb Company; Forest Laboratories, Inc.; Janssen Pharmaceuticals, Inc.; Johnson & Johnson; Lundbeck; Mitsubishi Tanabe Pharma Corporation; Moksha8 Pharmaceuticals Inc.; Otsuka; Pfizer Inc.; Purdue Pharma; Shire; Sunovion Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Limited.
Ms. Judd reports that she serves on the speakers bureau for Sunovion Pharmaceuticals Inc. She is a consultant for Sunovion Pharmaceuticals Inc.
Dr. Mattingly reports that he receives research grants from Akili; Alcobra Pharma; Alkermes; Allergan; Boehringer Ingelheim; Forum Pharmaceuticals Inc.; Janssen Pharmaceuticals, Inc.; Medgenics, Inc.; NLS-1 Pharma AG; Reckitt Benckiser Group; Shire; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.
He serves as a consultant for Alkermes, Allergan, Forum Pharmaceuticals Inc.; Lundbeck; Merck & Co., Inc.; Otsuka America Pharmaceutical, Inc.; Perdue Pharma L.P.; Rhodes Pharmaceuticals L.P.; Shire; Sunovion Pharmaceuticals, Inc.; Takeda Pharmaceuticals U.S.A.; and Vanda Pharmaceuticals.
He receives speaker fee's from Allergan, Lundbeck, Merck & Co., Inc.; Otsuka America Pharmaceutical, Inc.; Shire; Sunovion Pharmaceuticals Inc.; Takeda Pharmaceuticals U.S.A.; and Vanda Pharmaceuticals.
Eva Hardy, MS, RN, ANP-B (peer reviewer) has no disclosures to report.
Kashemi D. Rorie, PhD (planning committee) has no disclosures to report.
Sharon Tordoff, CHCP (planning committee) has no disclosures to report.
Jan Perez, CHCP (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).